Background/Objectives: Antimicrobial resistance (AMR) is a major global health threat. In patients undergoing cataract surgery, AMR complicates infection control, particularly efforts to reduce the risk of endophthalmitis—a rare but severe postoperative complication. This article reviews country-specific strategies for endophthalmitis prevention, focusing on antimicrobial use. Methods: Ophthalmology experts from 10 countries contributed national perspectives on infection prevention. Official guidelines served as the primary basis for analysis; when unavailable, expert opinion and routine clinical practice were considered. Results: Routine preoperative antibiotic use is uncommon in 6 out of 10 countries. Instead, artificial tears and bacteriostatic or bactericidal treatments are frequently employed. One country allows optional antibiotic use, while 3 include it in routine preoperative care. For intraoperative management, antisepsis with 5–10% povidone-iodine is standard practice in 9 countries. Intracameral cefuroxime (typically 1 mg/0.1 mL) is widely used in 7 countries and considered essential in most countries. Postoperatively, broad-spectrum topical antibiotics, primarily fluoroquinolones, are typically prescribed, often as fixed-dose combinations with corticosteroids (8 countries), although duration and regimens vary. Conclusions: Despite national differences, povidone-iodine, intracameral cefuroxime, and topical fluoroquinolones are widely used. Preoperative antibiotic use varies, while postoperative regimens are more consistent. These practices reflect local AMR patterns, regulations, and available healthcare resources. Although broad-spectrum agents are generally preferred, they raise concerns about resistance. Tailoring prophylactic strategies to local microbiological profiles and limiting the duration of antibiotic therapy are key to balancing efficacy and stewardship. An individualized, evidence-based approach is essential to reduce endophthalmitis risk and address AMR challenges.
Herpetic uveitis, most commonly caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV), is a frequent cause of secondary glaucoma. Elevated intraocular pressure (IOP) in these patients is primarily due to inflammatory trabeculitis, trabecular meshwork obstruction, and steroid-induced mechanisms. IOP control is often challenging, and some cases require surgical intervention. Two patients without prior glaucoma developed refractory IOP elevation following herpetic uveitis. Clinical evaluation included tonometry, biomicroscopy, and monitoring of responses to medical and surgical therapy. Both patients received systemic antiviral therapy with valacyclovir. Medical antiglaucoma treatment alone failed to achieve adequate IOP control. In the first patient, glaucoma developed after active herpetic uveitis; in the second, after cataract surgery in an eye with a history of herpetic infection. Following preoperative antiviral preparation, trabeculectomy was performed, resulting in stable postoperative IOP. Herpetic secondary glaucoma can present with refractory IOP even in patients without prior glaucoma, and timely antiviral therapy and surgical management are essential for long-term control.
The management of ocular hypertension and the various forms of glaucoma during pregnancy and lactation represents a significant clinical challenge. The main concerns are related to the selection of an appropriate therapeutic strategy, with special attention paid to the risks associated with treatment for both the mother and the fetus or breastfed infant. There is no universally accepted management protocol for these patients. Owing to the understandable lack of randomized clinical trials in this population, there is currently no officially approved antiglaucoma medication for use during pregnancy or breastfeeding. Selective laser trabeculoplasty is an excellent option for reducing intraocular pressure during pregnancy and lactation, particularly in view of its favorable safety profile. Two clinical cases of patients with ocular hypertension and elevated intraocular pressure who underwent selective laser trabeculoplasty are presented. A sustained and significant reduction in intraocular pressure was achieved. In both cases, the need for antiglaucoma medication was eliminated throughout the follow-up period.